Effect of EGFR gene mutation in patients with TNBC treated with bevacizumab combined with gemcitabine

Objective: To investigate the effect of Epidermal Growth Factor Receptor (EGFR) gene mutation in patients with Triple Negative Breast Cancer(TNBC) treated with bevacizumabcombined with gemcitabine. Methods: 180 patients with triple-negative breast canceradmitted to our hospital from September 2011 to September 2013 were enrolled in this study. According to their DNA sequencing results, the patients were divided into EGFR mutation group and the non-mutation group, and according to the patient's genetic mutation type, patients in mutation group were divided into exon 19 deletion group, exon 21 mutation group. All patients were treated with bevacizumaband gemcitabine, and the prognosis of each group was compared. Results: EGFR mutations were found in 51 cases (28.3%). The sex ratio and smoking history of EGFR mutant group were significantly different (P 0.05). Adverse reactions were concentrated in the rash, diarrhea, with mild degree and tolerable. For the incidence of adverse reactions in three groups, the difference was not statistically significant (P>0.05). Conclusion: EGFR mutations are more sensitive in patients with triple-negative breast cancertreated with bevacizumaband gemcitabine, with better clinical efficacy, and the progression-free survival of tumors is prolonged. EGFR mutation has no significant effect on the safety of treatment.